Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience

Ibrutinib is highly effective in patients with relapsed or refractory mantle cell lymphoma (MCL) in major clinical trials. Although there has been a dramatic improvement in survival outcomes in the salvage setting, nonresponders to ibrutinib have a bleak prognosis. Therefore, this retrospective stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Young‐Woo, Yoon, Seugyun, Min, Gi June, Park, Sung‐Soo, Park, Silvia, Yoon, Jae‐Ho, Lee, Sung‐Eun, Cho, Byung‐Sik, Eom, Ki‐Seong, Kim, Yoo‐Jin, Kim, Hee‐Je, Lee, Seok, Min, Chang‐Ki, Lee, Jong Wook, Cho, Seok‐Goo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853811/
https://www.ncbi.nlm.nih.gov/pubmed/31560165
http://dx.doi.org/10.1002/cam4.2565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853811/
https://www.ncbi.nlm.nih.gov/pubmed/31560165
http://dx.doi.org/10.1002/cam4.2565

Ejemplares similares